Total amount: € 0,00
Online ISSN 1827-1847
Allie D. E., Patlola R. R., Hebert C. J., Ingraldi A., Lirtzman M. D., Wyatt C. H., Walker C. M.
Cardiovascular Institute of the South Lafayette, Louisiana, US
Targeted renal therapy (TRT) is a novel emerging treatment where high-dose fenoldopam (FEN), a selective renal dopamine-1 receptor agonist and renal arteriolar vasodilator, is infused into both renal arteries via the US Food and Drug Administration (FDA)-approved 5-Fr bifurcated Benephit PV Catheter Infusion System. TRT has been shown to significantly increase the glomerular filtration rate by 25% vs placebo and IV-FEN (P<0.001), which may have important clinical implications in contrast-induced nephropathy prophylaxis and during vascular and endovascular surgical procedures.